Home » Authors » Rainer B. Langen

Articles by Rainer B. Langen

Co.don Taking Cell Platform Public On Market In Germany

Feb. 7, 2001

By Rainer B. Langen

German Government Commits DM1.5B To Biotech Research

Jan. 31, 2001

By Rainer B. Langen

GPC, Byk Gulden Collaborate In Deal Worth Up To US$100M

Jan. 24, 2001

By Rainer B. Langen

MorphoSys Enters EUR22M Deal With Centocor Around HuCAL

Jan. 10, 2001

By Rainer B. Langen

Xantos Formed Around Platform To Perform Functional Genomics

Jan. 10, 2001

By Rainer B. Langen

MediGene's Genital Warts Drug Enters Phase III Clinical Trials

Jan. 10, 2001

By Rainer B. Langen

LION Adds Preclinical Capability Through $35M Trega Acquisition

Jan. 3, 2001

By Rainer B. Langen

Estonia Will Build National Gene Bank With SNPs Of 1M Citizens

Jan. 3, 2001

By Rainer B. Langen

Germans React To British Decision On Embryonic Stem Cell Cloning

Jan. 3, 2001

By Rainer B. Langen

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.